International AIDS Conference

Slides:



Advertisements
Similar presentations
What does sexual & reproductive health have to do with clinical trials? Providing contraception & reproductive health care helps.
Advertisements

Persistence of HPV in a cohort of female adolescents Erika Samoff, Emilia H. Koumans, Lauri E. Markowitz, Maya Sternberg, Mary K. Sawyer, David Swan, John.
The effect of gender specific HIV prevention interventions on heterosexual anal sex among men and women in substance abuse treatment Donald A. Calsyn,
 Try to determine causes and risk factors for disease by drawing connections between behaviors or exposures and diseases through observation alone.
Maurice Cook ( EM Designs Group, Inc.) The End of AIDS Transmission? Robert M Grant, June 2012.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
Behavioral and Demographic Risk Factors for Bacterial Vaginosis among Wyoming Women Presented by Jennifer Chase, MS 12 th Annual Maternal & Child Health.
HIV Science Update: From Rome to Addis – Biomedical Prevention Elly T Katabira, FRCP Department of Medicine Makerere University College of Health Sciences.
Use of Antivirals in Prevention Oral and Topical Prophylaxis
Dr Himani. Foams or creams that people can use in vagina or rectum during sex to prevent transmission Currently, there is no vaccine to prevent HIV. This.
Microbicide Research: A Promising HIV/AIDS Prevention Strategy for Women Roberta Black, Ph.D. Division of AIDS, National Institute of Allergy and Infectious.
EVOLUTION OVER TIME – LOW RISK GROUP -The presence or absence of a particular Lactobacillus species appeared to remain constant throughout the study (Figure.
XIX International AIDS Conference
Microbicides for HIV Prevention Pamina M. Gorbach, Epidemiology & Infectious Diseases UCLA.
High Prevalence of Sexual Minority Status in a Sample of Women at High Risk for HIV Infection: Associated Individual-level Factors and Sexual Risk Behaviors.
Impact of HSV-2 suppressive therapy with daily acyclovir on HIV-1 disease progression: a randomized placebo- controlled trial in Rakai, Uganda Steven J.
DEVELOPING DUAL COMPARTMENT MPTS THAT WORK UP FRONT AND FROM BEHIND José Fernández Romero Population Council September 9, 2015.
Looking back, looking forward: what we know and don’t know about oral PrEP and tenofovir gel for preventing HIV in women Jared Baeten MD PhD Departments.
Looking back, looking forward: what we know and don’t know about oral PrEP and tenofovir gel for preventing HIV in women Jared Baeten MD PhD Departments.
Increased exposure to an HIV risk reduction protocol associated with a reduction in drug abuse severity Louise F. Haynes 1 ; Rickey E. Carter 1 ; Amy E.
Moving the Rectal Microbicide Agenda Forward; Results from a Scientific, Ethical, and Community Consultative Process Ian McGowan MD PhD FRCP University.
What Is Currently in the Pipeline & What is Ideal for an ARV-based Prevention Candidate? Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID,
When Will Women Have Choices? Sharon Hillier University of Pittsburgh School and Medicine Microbicide Trials Network IAS, Washington DC, July 26, 2012.
Implications of Anal Intercourse and Rectal use of Products in Vaginal Microbicide Trials Ian McGowan MD PhD FRCP.
Welcome South Africa 4 Rectal Microbicides A Stakeholder Consultation on Rectal Microbicide Research and Advocacy Please sign in.
© Guidant 2005 Surrogate Endpoints and Non-randomized Trials Roseann White Humble Biostatistician.
N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Pre-exposure Prophylaxis for HIV Prevention Efficacy and the importance of adherence Joanne Stekler,
Epidemiology of STD. Change in incidence (simple access to antibiotic, change to sexual behavior, multiple partner, low age of sexual contact, addiction,
Bacterial vaginosis, intravaginal practices and HIV genital shedding: implications for HIV transmission and women’s health Maria L Alcaide M.D. Associate.
Three-Year Outcomes of the Surgery for Trichiasis, Antibiotics to Prevent Recurrence Trial Woreta F, Munoz B, Gower E, Alemayehu W, West SK. Three-year.
Looking Ahead to MTN-017 Ross D. Cranston MD, FRCP Microbicide Trials Network IRMA.
HIV and Women Collaborating Across Borders to Advance the Health of Women IAS 2012 Gina M. Brown, M.D. July 22, 2012.
HIV Prevention for Transgender Populations JAIDS Supplement Launch Tonia Poteat, PhD, MPH, PA-C Johns Hopkins School of Public Health Baltimore, Maryland,
Pre-exposure Prophylaxis (PrEP) for HIV Prevention: What’s the Future? Joanne Stekler, MD MPH Assistant Professor of Medicine University of Washington.
Seeking HIV-testing Only: Missed Opportunity for HIV Prevention?
Acquisition of STIs among Women Using a Variety of Contraceptive Options: A Prospective Study among High-Risk African Women Flavia Matovu Kiweewa, Elizabeth.
HPTN 071 (PopART): Have we reached the targets after two years of the PopART intervention IAS Paris July 2017 Richard Hayes.
Regulatory Considerations for Approval: FDA perspective
“No conflicts of interest to declare”
Microbicides Trial Network
High level of retention and adherence at week 48 for MSM and TGW enrolled in the PrEP Brasil demonstration study Beatriz Grinsztejn, Brenda Hoagland, Ronaldo.
Prevalence of Sexually Transmitted Infections and Bacterial Vaginosis among Female Adolescents in the United States: Data from the National Health and.
Vaginal bacteria associated with increased risk of HIV acquisition in African women McClelland RS, Lingappa J, John-Stewart G, Kinuthia, Yuhas K, Jaoko.
The vaginal microbiota: the first line of defense against HIV
Module 4 (c) Stopping PrEP
Contraceptive Hormone Induced Changes - CHIC
Rectal Microbicides: Where We’re Heading
On behalf of The MTN-020/ASPIRE Study Team
Dapivirine Safety MTN 025 Training.
Vaccine Efficacy, Effectiveness and Impact
On Demand PrEP for Men at High Risk for HIV IPERGAY
MTN-036 Study of Extended Duration Dapivirine Vaginal Ring for HIV Prevention How do I know if I’m Eligible to join? Women who join the study must.
Role of Explant Tissue Infection Assays Ian McGowan MD DPhil FRCP University of Pittsburgh, PA, USA 26th July, Paris, France Wednesday October 7th 15.
Neal B, et al. Diabetes Care 2015;38:403–411
Emilia H. Koumans, Fujie Xu, Maya Sternberg, Lauri E. Markowitz
A study of high risk African American women, 15 to 21 years of age
Overview.
The Vaginal Microbiome During Pregnancy
Rectal Gels for PrEP Are They an Option?
100 Partners PrEP[5] Efficacy 75% Adherence 81% 80
The post-intervention effects of conditional cash transfers for HIV/STI prevention: a randomized trial in rural Tanzania Damien de Walque (The World Bank)
M Javanbakht, S Guerry, LV Smith, P Kerndt
Vaginal and endocervical microorganisms in symptomatic and asymptomatic non- pregnant females: risk factors and rates of occurrence  C. Tibaldi, N. Cappello,
José Bauermeister PhD, MPH University of Pennsylvania MTN BRWG Member
Medical-Surgical Nursing: Concepts & Practice
Rectal Microbicide Protocol Status
Research Techniques Made Simple: Interpreting Measures of Association in Clinical Research Michelle Roberts PhD,1,2 Sepideh Ashrafzadeh,1,2 Maryam Asgari.
Contraceptive Hormone Induced Changes - CHIC
Innovation in HIV Prevention Research Workshop
Refilwe Phemelo Molatlhegi
Presentation transcript:

International AIDS Conference IMPACT OF VAGINAL MICROBIOTA ON GENITAL TISSUE AND PLASMA CONCENTRATIONS OF DAPIVIRINE Sharon L Hillier, Leslie A Meyn, Katherine Bunge, Michele Austin, Bernard J Moncla, Charlene S. Dezzutti, Brid Devlin, Mark Marzinke, Craig Hendrix and Lisa Rohan for the FAME Team University of Pittsburgh and Magee-Womens Research Institute, Pittsburgh, PA; the International Partnership for Microbicides, Silver Springs, MD and Johns Hopkins University, Baltimore, MD International AIDS Conference Paris, France July 25, 2017

Tenofovir gel effective against HIV with Lactobacillus dominance Using adjusted Cox proportion hazard models, the HIV incidence rate in women with Lactobacillus dominance was 2.7 and 6.9 per 100 women-years in the tenofovir and placebo arms, respectively, translating to relative reduction of the rate of HIV-1 infection of 61% offered by tenofovir. [As the analysis compares HIV outcomes based on LD status, which neither the trial participants nor the investigators were aware of at randomization, overall random allocation in the CAPRISA 004 trial is expected to lead to comparable groups of women assigned to tenofovir or placebo gel in each of the LD and non-LD strata ] Klatt, et al. Science Volume 356(6341):938-945. June 2, 2017

What does the microbiota do to tenofovir in vitro? Klatt, et al. Science Volume 356(6341):938-945. June 2, 2017

Limitations of Published Data Women having greater numbers of partners and more frequent sexual activity at greater risk of BV and HIV; association between BV and apparent decreased efficacy in CAPRISA-04 trial could be attributed to unmeasured differences in behavior Degradation of tenofovir in presence of G vaginalis was demonstrated within hours in vitro, but this may not replicate in vivo conditions. Klatt, et al. Science Volume 356(6341):938-945. June 2, 2017

Connecting the Dots In vitro studies of microbes and drugs Results from the trial FAME trials: Timed in vivo exposure with direct measurement of drug in plasma and tissues after accounting for differences in the microbiome Hillier et al, CROI 2017 Klatt, et al. Science Volume 356(6341):938-945. June 2, 2017 Klatt, et al. Science Volume 356(6341):938-945. June 2, 2017

Objective and Hypothesis Objective: To evaluate whether vaginal microbiota associated with BV impact dapivirine concentrations in genital tract tissues and plasma following vaginal application. Hypothesis: Vaginal microbiota associated with BV will not decrease genital tract tissue and plasma levels of dapivirine

Study Population 66 healthy, nonpregnant women from Pittsburgh, PA, USA using effective contraception Asymptomatic, HIV-, negative for chlamydia, gonorrhea, trichomoniasis Characteristics: 76% unmarried 67% White, 27% Black

Study Design drug applied Tenofovir or dapivirine (film or gel) applied in clinic Collect: vaginal swabs for qPCR for microbiota drug applied daily at home Collect plasma, CVL and vaginal fluid for drug levels 2 hours Collect: Plasma Cervical biopsy Insert 7th dose in clinic Bunge, et al, CROI 2016 and Hillier et al, CROI 2017

Methods qPCR performed from vaginal swab samples collected at baseline Gardnerella vaginalis Lactobacillus crispatus, L jensenii, L gasseri, Bacterial vaginosis detected using Nugent criteria from a Gram stained vaginal smear collected at baseline Statistics: Relationship between vaginal microbiota and TFV or dapivirine concentrations was assessed using linear regression models A quadratic term was included in the tenofovir models with G. vaginalis to improve model fit. Reported P-values are from the global F-test. 

Tenofovir and Dapivirine: Tissue and Plasma LB dominant Genital epithelium Plasma Vaginal administration of tenofovir or dapivirine BV

Drug Level in Plasma vs Nugent Score (Score of 0-3 Lactobacillus dominant) Hillier et al, CROI 2017

Drug Level in Plasma vs Concentration of G vaginalis Hillier et al, CROI 2017

Drug Level in Plasma vs quantity of L crispatus, L jensenii or L gasseri Hillier et al, CROI 2017

Drug Levels in Cervical Tissue vs Nugent Score

Drug Levels in Cervical Tissue vs Concentration of G vaginalis Hillier et al, CROI 2017

Drug Levels in Cervical Tissue vs L crispatus, L jensenii or L gasseri Hillier et al, CROI 2017

Conclusions In contrast to tenofovir, genital and plasma concentrations of dapivirine were not decreased by bacteria associated with BV. These data suggest that the levels of dapivirine following vaginal application should not be impacted by the microbiota associated with bacterial vaginosis. This is supportive of the ASPIRE study results 40% of women had bacterial vaginosis at baseline. No difference in the efficacy of the dapivirine ring in women with bacterial vaginosis and in those without bacterial vaginosis at baseline (39% vs. 21%, P=0.4 for interaction). (NEJM 2017 Mar 9;376: 995-6 This emphasizes the need for HIV-1 prevention products that work in women with vaginal dysbiosis.

Acknowledgements Study participants National Institute of Allergy and Infectious Diseases, National Institutes of Health, Grant AI082639 and UL1 TR000005. CONRAD was the regulatory sponsor of the tenofovir trial and donated tenofovir drug substance and some study product. IPM was the regulatory sponsor for the dapivirine trial and donated drug substance and study product.